These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 23830474)
1. Reply from author re: Stephan Madersbacher. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions. Eur Urol 2013;64:257-9: OnabotulinumtoxinA for idiopathic overactive bladder symptoms: some answers but even more questions. Chapple CR Eur Urol; 2013 Nov; 64(5):e100-1. PubMed ID: 23830474 [No Abstract] [Full Text] [Related]
2. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions. Madersbacher S Eur Urol; 2013 Aug; 64(2):257-9. PubMed ID: 23731721 [No Abstract] [Full Text] [Related]
3. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population. Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R; Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394 [TBL] [Abstract][Full Text] [Related]
5. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. Herschorn S; Kohan A; Aliotta P; McCammon K; Sriram R; Abrams S; Lam W; Everaert K J Urol; 2017 Jul; 198(1):167-175. PubMed ID: 28161352 [TBL] [Abstract][Full Text] [Related]
6. Treatment of overactive bladder with botulinum toxin: are there more challenges to deal with? Apostolidis A Eur Urol; 2012 Sep; 62(3):515-7. PubMed ID: 22673007 [No Abstract] [Full Text] [Related]
7. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin as a treatment for refractory overactive bladder. Harris S; Rizzolo D JAAPA; 2016 Feb; 29(2):1-4. PubMed ID: 26818640 [TBL] [Abstract][Full Text] [Related]
9. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Cruz F; Nitti V Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Tincello DG; Kenyon S; Abrams KR; Mayne C; Toozs-Hobson P; Taylor D; Slack M Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796 [TBL] [Abstract][Full Text] [Related]
11. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. Kulaksizoglu H; Parman Y Parkinsonism Relat Disord; 2010 Sep; 16(8):531-4. PubMed ID: 20637678 [TBL] [Abstract][Full Text] [Related]
12. Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder. Chapple C Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S1. PubMed ID: 25042136 [No Abstract] [Full Text] [Related]
13. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Cui Y; Wang L; Liu L; Zeng F; Niu J; Qi L; Chen H Urol Int; 2013; 91(4):429-38. PubMed ID: 23970316 [TBL] [Abstract][Full Text] [Related]
14. Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. Onabotulinumtoxina. Doggweiler R J Urol; 2011 Jun; 185(6):2023-4. PubMed ID: 21496846 [No Abstract] [Full Text] [Related]
15. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110 [TBL] [Abstract][Full Text] [Related]
16. Botulinum-A Toxin's efficacy in the treatment of idiopathic overactive bladder. Moga MA; Banciu S; Dimienescu O; Bigiu NF; Scarneciu I J Pak Med Assoc; 2015 Jan; 65(1):76-80. PubMed ID: 25831681 [TBL] [Abstract][Full Text] [Related]
17. Changing treatments for overactive bladder. Waine E; Stott M Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960 [TBL] [Abstract][Full Text] [Related]
18. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310 [TBL] [Abstract][Full Text] [Related]
19. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder. Ellsworth P; Travis M Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617 [TBL] [Abstract][Full Text] [Related]